Guillermo Rossiter

1.1k total citations
24 papers, 867 citations indexed

About

Guillermo Rossiter is a scholar working on Surgery, Genetics and Epidemiology. According to data from OpenAlex, Guillermo Rossiter has authored 24 papers receiving a total of 867 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Surgery, 10 papers in Genetics and 8 papers in Epidemiology. Recurrent topics in Guillermo Rossiter's work include Inflammatory Bowel Disease (10 papers), Helicobacter pylori-related gastroenterology studies (5 papers) and Microscopic Colitis (5 papers). Guillermo Rossiter is often cited by papers focused on Inflammatory Bowel Disease (10 papers), Helicobacter pylori-related gastroenterology studies (5 papers) and Microscopic Colitis (5 papers). Guillermo Rossiter collaborates with scholars based in United States, Japan and Canada. Guillermo Rossiter's co-authors include Moisés Guelrud, Sonia Mendoza, María Isabel Villegas, Keith Usiskin, Jean‐Frédéric Colombel, Brian G. Feagan, Bruce E. Sands, Jamie S. Barkin, Paul F. Souney and Yihan Lu and has published in prestigious journals such as Nature Medicine, Gastroenterology and The American Journal of Gastroenterology.

In The Last Decade

Guillermo Rossiter

21 papers receiving 848 citations

Peers

Guillermo Rossiter
Brian McKaig United Kingdom
A. Skarstein Norway
Baili Chen China
Silvia Kellermeier Switzerland
K Jaśkiewicz South Africa
Rintaro Narisawa Japan
Seung‐Bum Ryoo South Korea
A. Christopher Stevens United States
Yolanda Arce Spain
Naotake Akutsu Japan
Brian McKaig United Kingdom
Guillermo Rossiter
Citations per year, relative to Guillermo Rossiter Guillermo Rossiter (= 1×) peers Brian McKaig

Countries citing papers authored by Guillermo Rossiter

Since Specialization
Citations

This map shows the geographic impact of Guillermo Rossiter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guillermo Rossiter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guillermo Rossiter more than expected).

Fields of papers citing papers by Guillermo Rossiter

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guillermo Rossiter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guillermo Rossiter. The network helps show where Guillermo Rossiter may publish in the future.

Co-authorship network of co-authors of Guillermo Rossiter

This figure shows the co-authorship network connecting the top 25 collaborators of Guillermo Rossiter. A scholar is included among the top collaborators of Guillermo Rossiter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guillermo Rossiter. Guillermo Rossiter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sullivan, Ryan J., Katy K. Tsai, Anna C. Pavlick, et al.. (2025). Phase 1b Study of Tovorafenib, Plozalizumab or Vedolizumab Plus Standard-of-Care Immune Checkpoint Inhibitors in Patients with Advanced Melanoma. Journal of Cancer. 16(13). 3797–3809.
2.
Goto, Tatsunori, Hiroshi Okamura, Takashi Ikeda, et al.. (2025). Vedolizumab for prevention of lower-GI acute GVHD in the Japanese subgroup analysis of the phase 3 GRAPHITE study. International Journal of Hematology. 122(1). 93–105. 1 indexed citations
3.
Chen, Minhu, et al.. (2025). Efficacy and safety of intravenous vedolizumab treatment in Chinese patients with moderate-to-severe Crohn's disease. Clinics and Research in Hepatology and Gastroenterology. 49(6). 102591–102591.
4.
Chen, Jingjing, Y. Takanami, Johan Jansson, & Guillermo Rossiter. (2024). Practical considerations of promising zone design for interim sample size Re-estimation: An application to GRAPHITE for graft vs host disease. Contemporary Clinical Trials. 148. 107765–107765.
5.
Chen, Yi‐Bin, Mohamad Mohty, Robert Zeiser, et al.. (2024). Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial. Nature Medicine. 30(8). 2277–2287. 20 indexed citations
6.
Sands, Bruce E., Brian G. Feagan, William J. Sandborn, et al.. (2019). Mongersen (GED-0301) for Active Crohn's Disease: Results of a Phase 3 Study. The American Journal of Gastroenterology. 115(5). 738–745. 64 indexed citations
7.
Rossiter, Guillermo, et al.. (2017). PD-008 A Study of Oral Mongersen (GED-0301) on Endoscopy and Clinical Activity (Stool Frequency and Abdominal Pain) in Crohn's Disease. Inflammatory Bowel Diseases. 23. 1 indexed citations
8.
Feagan, Brian G., Bruce E. Sands, Guillermo Rossiter, et al.. (2017). Effects of Mongersen (GED-0301) on Endoscopic and Clinical Outcomes in Patients With Active Crohn’s Disease. Gastroenterology. 154(1). 61–64.e6. 54 indexed citations
9.
Feagan, Brian G., et al.. (2017). OP019 Correlation of clinical and endoscopic outcomes in patients with active Crohn's disease treated with mongersen (GED-0301). Journal of Crohn s and Colitis. 11(suppl_1). S11–S12. 2 indexed citations
10.
Feagan, Brian G., Jean‐Frédéric Colombel, Guillermo Rossiter, et al.. (2017). Correlation of Clinical and Endoscopic Outcomes in Patients with Active Crohn’s Disease Treated with Mongersen (GED-0301). Gastroenterology. 152(5). S198–S198. 1 indexed citations
11.
Monteleone, Giovanni, Antonio Di Sabatino, Sandro Ardizzone, et al.. (2015). 826 Impact of Severity and Duration of Active Crohn's Disease on the Clinical Efficacy of Mongersen (GED-0301), an Oral Smad7 Antisense Oligonucleotide. Gastroenterology. 148(4). S–162. 6 indexed citations
12.
13.
Laine, Loren, Philip O. Katz, David A. Johnson, et al.. (2010). Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate-to-severe erosive oesophagitis - the results of two double-blind studies. Alimentary Pharmacology & Therapeutics. 33(2). 203–212. 22 indexed citations
14.
Rossiter, Guillermo, et al.. (1996). Expression of transforming growth factors alpha and beta in colonic mucosa in inflammatory bowel disease. Gastroenterology. 110(4). 975–984. 328 indexed citations
15.
Guelrud, Moisés, et al.. (1995). Endoscopic treatment in type II pancreatic sphincter dysfunction. Gastrointestinal Endoscopy. 41(4). 398–398. 32 indexed citations
16.
Guelrud, Moisés, et al.. (1992). The effect of vasoactive intestinal polypeptide on the lower esophageal sphincter in achalasia. Gastroenterology. 103(2). 377–382. 29 indexed citations
17.
Guelrud, Moisés, et al.. (1991). Effect of local instillation of alcohol on sphincter of Oddi motor activity: combined ERCP and manometry study. Gastrointestinal Endoscopy. 37(4). 428–432. 22 indexed citations
18.
Guelrud, Moisés, et al.. (1991). High Vasoactive Intestinal Polypeptide Plasma Levels in Patients with Barrett's Esophagus. Scandinavian Journal of Gastroenterology. 26(5). 572–576. 5 indexed citations
19.
Guelrud, Moisés, Sonia Mendoza, Guillermo Rossiter, & María Isabel Villegas. (1990). Sphincter of oddi manometry in healthy volunteers. Digestive Diseases and Sciences. 35(1). 38–46. 115 indexed citations
20.
Guelrud, Moisés, et al.. (1988). Effect of nifedipine on sphincter of Oddi motor activity: Studies in healthy volunteers and patients with biliary dyskinesia. Gastroenterology. 95(4). 1050–1055. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Brian McKaig Breakdown of academic impact, for papers by A. Skarstein Breakdown of academic impact, for papers by Baili Chen Breakdown of academic impact, for papers by Silvia Kellermeier Breakdown of academic impact, for papers by K Jaśkiewicz Breakdown of academic impact, for papers by Rintaro Narisawa Breakdown of academic impact, for papers by Seung‐Bum Ryoo Breakdown of academic impact, for papers by A. Christopher Stevens Breakdown of academic impact, for papers by Yolanda Arce Breakdown of academic impact, for papers by Naotake Akutsu
Rankless by CCL
2026